UHMK1 (KIS) is a nuclear serine/threonine kinase that possesses a U2AF homology motif and phosphorylates and regulates the activity of the splicing factors SF1 and SF3b155.
Abstract
UHMK1 (KIS) is a nuclear serine/threonine kinase that possesses a U2AF homology motif and phosphorylates and regulates the activity of the splicing factors SF1 and SF3b155.
Mutations in these components of the spliceosome machinery have been recently implicated in leukemogenesis. The fact that UHMK1 regulates these factors suggests that UHMK1 might be involved in RNA processing and perhaps leukemogenesis. Here we analyzed UHMK1 expression in normal hematopoietic and leukemic cells as well as its function in leukemia cell line.
In the normal hematopoietic compartment, markedly higher levels of transcripts were 
Introduction
UHMK1 was first identified as a kinase that interacts with Stathmin (KIS) [1] , an important regulator of microtubule dynamics. Since then it has been described to interact with a range of proteins, such as peptidylglycine α -amidating monooxygenase (PAM) [2] ; cyclin dependent kinase inhibitor (CDKI) p27 KIP1 [3] ; splicing factors SF1 [4] and SF3b155 [5] ; components of the neuronal RNA granules NonO, KIF3A and eEF1A [6] ; proliferation marker PIMREG [7] ; and RNA-binding proteins CPEB1, CPEB2 and CPEB3 [8] , shedding light on different functions of UHMK1 in diverse cellular processes.
UHMK1 is ubiquitously, but preferentially, expressed in neural systems [9] , its mRNA levels increase gradually during postnatal development, reaching highest levels in the mature brain.
Not surprisingly, most of UHMK1-related functions have been addressed in the context of adult nervous system [6, 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] .
Other than the neuronal milieu, important functions of UHMK1 are conferred to its unique feature. UHMK1 is the only known kinase to possess the N-terminal kinase core juxtaposed to a C-terminal U2AF homology motif (UHM), which shares significant similarity to the SF1-binding UHM domain of the splicing factor U2AF 65 [19] .
Through the UHM motif, UHMK1 is capable of interacting with splicing factors such as SF1 and SF3b155 [5] . Upon interaction, UHMK1 phosphorylates SF1, which in turn favors the formation of a U2AF 65 -SF1-RNA complex at 3' splice site, an event known to take place during the early steps of spliceosome assembly [4] . Moreover, UHMK1 expression is necessary for normal phosphorylation of SF1 in vivo [16] . Thus UHMK1 may participate in RNA splicing.
Another important function described for UHMK1 is its ability to positively regulate cell cycle progression. Upon mitogen activation, UHMK1 is upregulated and phosphorylates p27 Kip1 on serine 10 (S10), promoting its nuclear export and release of its inhibitory effect on . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  cell cycle [3] . Therefore, UHMK1 promotes cell cycle re-entry by inactivating p27 Kip1 following growth factor stimulation, as demonstrated during proliferative response of vascular smooth cells (VSMC) [20] and corneal endothelial cells (CEC) [21, 22] . Accordingly, deletion of UHMK1 abolished VSMC proliferation whereas it increased its migratory activity [23] .
Thus abnormally elevated UHMK1 activity, which is expected to relieve cells from growth inhibition dependent on p27
Kip , could be involved in some aspects of tumor development. Indeed, Zhang and coworkers demonstrated that the UHMK1 silencing enhances anti-tumor activity of erlotinib and could be a molecular target for combinatorial treatment in EGFR TKI-resistant cases of breast cancer [24] . More recently, UHMK1 was described in a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for detection of serous ovarian cancer [25] .
We described UHMK1 interaction with PIMREG (previously known as CATS; FAM64A), a protein highly expressed in leukemia cells, know to interact with and influence the subcellular localization of the leukemic fusion protein PICALM/MTT10 [26] . We suggested a possible role of UHMK1-PIMREG interaction in PICALM/MTT10 mediated leukemogenesis [7] .
Interestingly, an increasing amount of data has pointed to altered splicing machinery as a novel mechanism in leukemogenesis [27] . Somatic mutation has been found in genes coding for splicing factors in patients with diverse hematological malignancies, including the UHMK1 substrates SF1 and SF3b155 [28, 29] .
The described role for UHMK1 in controlling cell cycle progression, its interaction with a proliferation marker and most importantly is function in regulation of the splicing factors commonly found mutated in hematological malignancies, prompted us to investigate a . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  possible function of UHMK1 in the hematopoietic compartment and possibly leukemogenesis.
Here we show that UHMK1 expression is upregulated upon differentiation of hematopoietic cells. Of note, depletion of its protein does not interfere with proliferation or cell cycle progression of leukemic cells but rather it increases the clonogenicity of the U937 leukemia cell line.
. All cells were subsequently used for RNA extraction.
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Materials and methods

Sorting of human hematopoietic cell subpopulation
Patient samples
Total bone marrow samples obtained from healthy donors (n=19), MDS (n=45), AML (n=42) and ALL (n=22) patients were analyzed. All patients included in the study were untreated at the time of sample collection. Patients' characteristics are depicted in Detector System (Applied Biosystems, Foster City, CA, USA).
Differentiation of cell lines and primary CD34 + cells
RNA and protein samples of leukemia cells and primary peripheral blood CD34 + cells induced to differentiate were obtained from previous studies [32, 33] . .
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Peripheral blood lymphocytes (PBLs) activation
Human resting PBLs were prepared from peripheral blood of healthy donors by standard Ficoll/Hypaque gradient centrifugation and stimulated with phytohemaglutinin (PHA) as previously described [34] .
Quantitative PCR
Total RNA was extracted using Trizol® or RNeasy ® Mini or Micro Kit (Qiagen, Hilden, Germany). DNAse I treated RNA was reverse transcribed with oligo dT primers and
RevertAid™ First Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-Rot, Germany).
Reactions were carried out with Maxima SYBR Green qPCR master mix, according to the manufacture's protocol (MBI Fermentas). Plates were run and analyzed using the 7500 RealTime PCR Systems (Life Technologies, Carlsbad, CA, USA). HPRT and GAPDH were used as endogenous controls, and relative gene expression was calculated by 2 -ΔΔCt equation [35] .
Immunoblotting
Cellular lysates were electrophoresed on 10-12% SDS-PAGE and transferred to 
Methylthiazoletetrazolium (MTT) assay
For MTT assay cells were seeded in 96-well plates at density of 2. . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;
Apoptosis assays
Cells were washed with ice-cold PBS and stained with annexin V and PI (BD Biosciences Pharmingen, California, USA) for 15 minutes at RT. Apoptosis analysis was performed using FACSCalibur (Becton-Dickinson) and FACSDiva software (BD Biosciences Pharmingen). Ten thousand events were acquired for each sample.
Migration assay
Migration assay was performed in a 5µm pore-sized transwell plates (Costar, 
Statistical analysis
Statistical analysis was performed using GraphPad Instat Prism 5 (GraphPad Software Inc., San Diego, CA, USA) and the Statistical Analysis System (SAS) for Windows 9.4 (SAS Institute Inc, Cary, NC, USA). Two-tailed Student's t test was used for paired measured factors. Results are shown as mean ± standard deviation of mean (SEM). Cox regression model was used to estimate overall survival (OS) and event-free survival (EFS) for patients
with MDS. The stepwise process of selection was used for multivariate analysis. OS was defined from the time of sampling to the date of death or last follow-up, and EFS was defined as the time of sampling to the date of progression to high-risk MDS or AML with myelodysplasia-related changes, date of death or last follow-up. A p value <0.05 was considered as statistically significant.
. Table 2) .
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UHMK1 silencing does not affect cell cycle progression of U937 leukemia cells
The U937 leukemia cell line was transduced with lentiviral particles expressing a pool of multiple shRNA targeting the UHMK1 mRNA. UHMK1 was efficiently depleted at both mRNA and protein levels in shUHMK1 transduced cells compared to shControl cells ( Figure   4A ). UHMK1 silencing did not affect proliferation or viability of U937 cells, as assessed by MTT assay. Also, no difference in apoptosis or the percentage of cells in the different .
CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  phases of the cell cycle was observed, as assessed by annexin-V/PI staining and analysis of DNA content, respectively ( Figure 4B-D) . Transwell chemotaxis assay was performed in order to assess the migration of shUHMK1 and shControl cells towards the chemotactic stimulus of FBS (10% Fetal Bovine Serum) and CXCL12. Cell migration was unaffected upon UHMK1 depletion ( Figure 4E ).
Since UHMK1 is an important regulator of p27 KIP , we assessed the protein expression and phosphorylation levels of p27 KIP (S10) on shUHMK1 transduced cells. No difference in the total amount of p27 KIP was observed in UHMK1 depleted cells compared to control.
Moreover, phosphorylation of p27 KIP on S10, a commonly targeted residue by UHMK1, was unaltered upon UHMK1 depletion ( Figure 4F ). This data confirms that proliferation of the U937 leukemia cells was not affected by silencing UHMK1 protein.
UHMK1 silencing increases clonogenicity of U937 leukemia cells
Colony formation assay was employed to assess the clonogenic potential of the UHMK1 depleted U937 cells on semisolid medium in the absence of growth factors.
UHMK1 silenced cells formed 50% more colonies than shControl cells, indicating an augmented autonomous clonal growth of these cells upon UHMK1 depletion ( Figure 5 ).
.
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Discussion
In order to explore UHMK1 function in the human hematopoietic compartment we performed an extensive analysis of UHMK1 expression in normal and malignant hematopoietic cells, during induced differentiation of primary CD34
+ cells and leukemia cell lines, and assessed the effect of UHMK1 silencing in the U937 leukemia cells.
Comparing UHMK1 expression in different subpopulations of the bone marrow or peripheral blood, we observed higher levels in the most differentiated cells (lymphocytes expression is upregulated in all types of differentiation tested, namely erythroid, megakaryocytic, monocytic and granulocytic differentiation. These results suggest a role of UHMK1 in hematopoietic cell differentiation. A similar suggestion of a possible role for UHMK1 in differentiation has been previously proposed for neuronal cells [9] , and more recently for osteoblasts and osteoclasts in bone metabolism [36] .
The function of UHMK1 as a regulator of cell cycle progression is well documented.
UHMK1 regulates the cyclin dependent kinase inhibitor p27 KIP and consequently the cell cycle progression [3] . Thus, it is expected that abnormally elevated UHMK1 activity could be .
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  involved in some aspects of tumor development. For this reason, we aimed to investigate UHMK1 expression on primary cells of patient samples with hematological malignancies. No aberrant expression was observed in patient samples of MDS, AML and ALL compared to healthy donors. However, high expression of UHMK1 was an independent prognostic factor for increased overall survival in our cohort of patients with MDS. To our knowledge this is the first time that the impact of UHMK1 expression on MDS survival outcomes has been addressed. Interestingly, UHMK1 is a kinase that phosphorylates the splicing factors SF3b1 and SF1 [4, 5] , commonly found mutated in MDS patients [29] . Nevertheless, mutations within UHMK1 have not been described yet. It is well known that splicing factor function is regulated through reversible phosphorylation events that contribute to assembly of regulatory proteins on pre-mRNA and therefore contributes to the splicing code [37] . It is tempting to speculate that the higher expression of UHMK1 would impact the regulation and/or function of its substrates SF3B1 and SF1 in MDS patients with better outcome.
Using a lentivirus-mediated shRNA knockdown, we demonstrated that UHMK1 silencing did not affect proliferation or cell cycle progression of U937 leukemia cells. This was supported by the unaltered levels of p27 KIP expression and S10 phosphorylation in UHMK1 depleted cells. Similarly, UHMK1 silencing in breast cancer cells also did not exhibit cell cycle arrest but did when in association with erlotinib [24] .
These results were at first confusing since UHMK1 knockdown in cancer cells was expected to reduce p27 KIP S10 phosphorylation, stabilize p27 KIP and enhanced growth arrest, as observed in other cell line models [3, 20, 23, 38] . On the other hand, cell proliferation and differentiation are two inversely correlated processes and the high levels of UHMK1 expression in differentiated hematopoietic cells seems contradictory to the proliferation promoting function of UHMK1.
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It is important to consider that UHKM1 function to overcome growth arrest induced by p27 KIP is dependent on mitogenic activation [3] . The fact that UHMK1 depletion did not affect the proliferation of leukemic cells could be explained by the fact that these cells are transformed proliferating, and not quiescent cells arrested in a p27 KIP dependent manner. In order to confirm the ability of UHMK1 to overcome p27 KIP dependent arrest, we analyzed UHMK1 expression after quiescent PBLs were induced to proliferate with PHA. Western blot analysis revealed a clear upregulation of UHMK1 in proliferating PBLs, compared to quiescent cells. Accordingly, we show massive increase of p27 KIP S10 phosphorylation and clear reduction of the total amount of the protein (Supplementary Figure 1) . Thus, UHMK1
can induce cell cycle progression in hematopoietic cells in order to release them from cell cycle arrest.
It was shown in an experimental mouse model of vascular wound repair that VMSC Uhmk1 -/-cells exhibit increased migratory activity [23] . We did not observe altered migration of UHMK1 silenced leukemia cells assessed by transwell system. The function of UHMK1 in VMSC migration is dependent on its ability to promote STATHMIN phosphorylation and degradation. In that report, the authors did not observe deregulation of STATHMIN in Uhmk1 -/-T cells suggesting that STATHMIN based function of Uhmk1 is cell type dependent [23] .
Most importantly, UHMK1 silencing boosted colony formation of the U937 cells plated on semisolid culture medium deprived of growth factor. These results suggest that UHMK1 plays a role in the autonomous clonal growth of U937 cells. It is tempting to speculate that the low levels of UHMK1 would render the cells with a more undifferentiated phenotype, and as a consequence turn these cells more clonogenic. Nevertheless, this hypothesis has to be further investigated.
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Disclosure statement
The author(s) declare that they have no competing interests. Western blot analysis of shControl and shUHMK1 total cell extracts blotted against anti-p27, anti-phospho-p27(S10) and anti-GAPDH, used as loading control. The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  percentage. Images of representative culturing plates are shown. Results are shown as mean ± SD of six independent triplicate experiments. *p < 0.05, Student's t test.
. CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/187385 doi: bioRxiv preprint first posted online Sep. 11, 2017;  Abbreviations: MDS, myelodysplastic syndromes; WHO, World Health Organization; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; del(5q), MDS with isolated del(5q); RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, refractory anemia with excess blast-1; RAEB-2, refractory anemia with excess blast-2; IPSS-R, Revised International Prognostic Scoring System; BM, bone marrow; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; a In MDS cohort, karyotype findings included very low risk: -Y (n=1), del(11q) (n=1); low risk: normal (n=34), del(5q) (n=1); intermediate risk: +8 (n=2), -7 (n=1), other (n=3); high risk: three abnormalities (n=0); and very high risk: >3 abnormalities (n=0).
b
In AML cohort, favorable risk karyotype included t(8;21) (n=2) and inv(16) (n=1), intermediate risk included normal (n=15) and other abnormalities not classified as favorable or adverse (n=7), and adverse risk included complex karyotype (≥ 4 unrelated abnormalities) (n=4), del(5q) (n=2) and -7 (n=3).
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